These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38316618)

  • 1. Bayesian meta-analysis for evaluating treatment effectiveness in biomarker subgroups using trials of mixed patient populations.
    Wheaton L; Jackson D; Bujkiewicz S
    Res Synth Methods; 2024 Jul; 15(4):543-560. PubMed ID: 38316618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing Bayesian hierarchical meta-regression methods and evaluating the influence of priors for evaluations of surrogate endpoints on heterogeneous collections of clinical trials.
    Collier W; Haaland B; Inker LA; Heerspink HJL; Greene T
    BMC Med Res Methodol; 2024 Feb; 24(1):39. PubMed ID: 38365599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Individual participant data from digital sources informed and improved precision in the evaluation of predictive biomarkers in Bayesian network meta-analysis.
    Umemneku-Chikere CM; Wheaton L; Poad H; Ray D; Andrade IC; Khan S; Tappenden P; Abrams KR; Owen RK; Bujkiewicz S
    J Clin Epidemiol; 2023 Dec; 164():96-103. PubMed ID: 37918640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IBIS: identify biomarker-based subgroups with a Bayesian enrichment design for targeted combination therapy.
    Chen X; Zhang J; Jiang L; Yan F
    BMC Med Res Methodol; 2023 Mar; 23(1):66. PubMed ID: 36941537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient testing of the biomarker positive and negative subgroups in a biomarker-stratified trial.
    Li L; Ivanova A
    Biometrics; 2024 Mar; 80(2):. PubMed ID: 38861372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Bayesian approach to subgroup identification.
    Berger JO; Wang X; Shen L
    J Biopharm Stat; 2014; 24(1):110-29. PubMed ID: 24392981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bayesian order constrained adaptive design for phase II clinical trials evaluating subgroup-specific treatment effect.
    Shan M; Guo B; Liu H; Li Q; Zang Y
    Stat Methods Med Res; 2023 May; 32(5):885-894. PubMed ID: 36919375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Causal assessment of surrogacy in a meta-analysis of colorectal cancer trials.
    Li Y; Taylor JM; Elliott MR; Sargent DJ
    Biostatistics; 2011 Jul; 12(3):478-92. PubMed ID: 21252079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Bayesian prediction model between a biomarker and the clinical endpoint for dichotomous variables.
    Jiang Z; Song Y; Shou Q; Xia J; Wang W
    Trials; 2014 Dec; 15():500. PubMed ID: 25528466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Semi-parametric Bayesian regression for subgroup analysis in clinical trials.
    Gamalo-Siebers M; Tiwari R
    J Biopharm Stat; 2019; 29(6):1024-1042. PubMed ID: 30747568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-STEPP with random effects.
    Wang XV; Cole B; Bonetti M; Gelber RD
    Res Synth Methods; 2018 Jun; 9(2):312-317. PubMed ID: 29281174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bayesian adjusted R2 for the meta-analytic evaluation of surrogate time-to-event endpoints in clinical trials.
    Renfro LA; Shi Q; Sargent DJ; Carlin BP
    Stat Med; 2012 Apr; 31(8):743-61. PubMed ID: 22161275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of subgroup identification methods in clinical drug development: Simulation study and regulatory considerations.
    Huber C; Benda N; Friede T
    Pharm Stat; 2019 Oct; 18(5):600-626. PubMed ID: 31270933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isotonic design for single-arm biomarker stratified trials.
    Li L; Ivanova A
    Stat Methods Med Res; 2024 Jun; 33(6):945-952. PubMed ID: 38573793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Model averaging for treatment effect estimation in subgroups.
    Bornkamp B; Ohlssen D; Magnusson BP; Schmidli H
    Pharm Stat; 2017 Mar; 16(2):133-142. PubMed ID: 27935199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simulation-based adjustment after exploratory biomarker subgroup selection in phase II.
    Götte H; Kirchner M; Sailer MO; Kieser M
    Stat Med; 2017 Jul; 36(15):2378-2390. PubMed ID: 28436046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data.
    Stijnen T; Hamza TH; Ozdemir P
    Stat Med; 2010 Dec; 29(29):3046-67. PubMed ID: 20827667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of Bayesian and frequentist methods in random-effects network meta-analysis of binary data.
    Seide SE; Jensen K; Kieser M
    Res Synth Methods; 2020 May; 11(3):363-378. PubMed ID: 31955519
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.